The event will review Aptinyx’s full pipeline of clinical development programs, with particular focus on NYX-2925, the company’s drug candidate in development for the treatment of chronic pain.

The program will feature a presentation by Key Opinion Leader (KOL) Richard Rauck, MD, board certified physician in pain medicine and anesthesiology at Carolinas Pain Institute.

The event will also include presentations from the Aptinyx management team discussing the company’s novel approach to discovering and developing NMDA receptor modulators, as well as reviews of each of the company’s clinical development programs. Aptinyx management will provide a deep-dive review of NYX-2925, the company’s first-in-class NMDA receptor positive allosteric modulator in development for the treatment of chronic pain.

A live question and answer session will follow.